Eric P. Winer
Dana-Farber Cancer Institute
Public scientific profile · Unclaimed
Built from public scholarly sources. Expertise is inferred by ScienceWe from publications and has not been confirmed by the scientist.
Top expertise
HER2/EGFR in Cancer Research
Strong evidence · 4 supporting papers · latest 2026
Breast Cancer Treatment Studies
Strong evidence · 7 supporting papers · latest 2026
Cancer Risks and Factors
Strong evidence · 1 supporting paper · latest 2026
Digital Radiography and Breast Imaging
Strong evidence · 1 supporting paper · latest 2026
Brain Metastases and Treatment
Solid evidence · 1 supporting paper · latest 2026
Cancer Genomics and Diagnostics
Solid evidence · 2 supporting papers · latest 2026
Ethics in Clinical Research
Solid evidence · 2 supporting papers · latest 2026
Medical Imaging Techniques and Applications
Solid evidence · 2 supporting papers · latest 2026
Publications (11)
Pathologic Complete Response (pCR) Rate and Predictors of Response to Taxane, Trastuzumab, and Pertuzumab in HER2‑Positive Breast Cancer: Secondary Analyses of EA1181/CompassHER2 pCR
2026DOIPMID 42623567
Impact of a Weight Loss Intervention on 1-Year Weight Change in Women With Stage II/III Breast Cancer
2026DOI
Tumor characteristics associated with tomosynthesis versus digital mammography in older women with screen-detected breast cancer
2026DOIPMID 42420682
Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab for Stage II to III, ERBB2 -Positive Breast Cancer
2026DOIPMID 42348190
Patient-reported outcomes from the TBCRC 022 study of neratinib and ado-trastuzumab emtansine for HER2-positive breast cancer brain metastases
2026DOIPMID 42501479
A composite 18F-FDG PET/CT and HER2 tissue-based biomarker to predict response to neoadjuvant pertuzumab and trastuzumab in HER2-positive breast cancer (TBCRC026)
2026DOI
Minimal Residual Disease via circulating tumor DNA Predicts Exceptional Response in HER2-Positive Metastatic Breast Cancer
2026DOIPMID 42528545
Spatial/molecular heterogeneity and treatment response in HER2+ early breast cancer: Translational analyses from the DAPHNe trial
2026DOI
Association between self-reported breast cancer knowledge and clinical trial participation in patients with triple-negative breast cancer
2026DOIPMID 42530769
8th International Consensus Guidelines for the management of advanced breast cancer (ABC8 Guidelines)
2026DOI
Invest where impact begins: recommendations from Breast Cancer Research Foundation Early Career Investigator Working Group (Part 1 of 2)
2026DOI
Organizations in sourced records
Affiliation evidence only — not confirmed current employment.
- Dana-Farber Cancer Institute
Source: OpenAlex · retrieved 2026-09-29